← All trials
NCT05517642
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 20, 2022
- Primary completion
- Apr 1, 2023
- Completion date
- Jul 1, 2023
- First posted
- Aug 26, 2022
- Last posted
- Nov 1, 2022
- Enrollment
- 540
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tianjin Cansino Biotechnology IncLead sponsor
- Hospital AmpangOverall official - principal investigator
- Kuala Lumpur General HospitalOverall official - principal investigator
- Hospital AmpangOfficial
- Kuala Lumpur General HospitalOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.